FNS may help ameliorate mixed trauma spectrum syndromes. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:237-240)”
“There are few published population-based data for psychogenic nonepileptic seizures (PNES). We prospectively identified first presentations of PNES from a population of 367,566, over 3 years. PNES were diagnosed in 68 patients, in 54 of whom the diagnosis was confirmed check details by video/EEG recording, indicating an incidence of 4.90/100,000/year. Median diagnostic delay was 0.6 +/- 0.2 year. At presentation with PNES, our patients already had high rates of psychological morbidity, medically unexplained
symptoms other than PNES, and economic dependence. At 3 months postdiagnosis, 27 of 54 patients (50.0%) were spell free. For 24 of the 27 patients (88.9%), spells ceased immediately on communication of the diagnosis. At Copanlisib 6 months, 24 of 54 patients (44.4%) were spell free. Poor early outcome was predicted by unemployment.
Our data suggest that early outcome is good in patients with recent-onset PNES, but some patients relapse quickly. (C) 2010 Elsevier Inc. All rights reserved.”
“CEA and CA19.9 are biomarkers routinely measured for monitoring treatment response in metastatic colorectal cancer (MCRC) patients, yet their predictive value during therapies containing new antineoplastic drugs (i.e. FOLFIRI/FOLFOX/Bevacizumab) has not yet been investigated.
Consecutive chemotherapy-naive MCRC patients treated with either standard chemotherapy-alone (FOLFIRI/FOLFOX) or chemotherapy+bevacizumab (FOLFIRI+bevacizumab) were included in the analysis. Patients PARP activation had to have serial biweekly measurement of CEA and CA19.9 available for at least three months of treatment. Primary study endpoint was Progression Free Survival (PFS). Biomarker levels and type of treatment as well as major
demographic and clinical factors were analyzed for their impact on PFS.
Out of 243 evaluated MCRC patients, 87 had biomarkers available as per inclusion criteria. Among all evaluated factors only type of treatment (chemotherapy-alone vs chemotherapy+bevacizumab) and baseline CA19.9 (> vs < normal) were independently associated with PFS, whilst neither baseline CEA nor biomarker reduction during therapy reached statistical significance. When patients with different baseline CA19.9 levels were analysed separately, only patients with abnormal CA19.9 benefited significantly from the administration of bevacizumab.
The current study demonstrated a significant predictive value of CA19.9, but not of CEA and biomarker reduction, for MCRC patients treated with new antineoplastic drugs. Moreover, only patients with abnormal baseline CA19.9 levels benefited significantly from bevacizumab.”
“Background: Malignant tumor cells may evoke the innate and adaptive immune systems.